Arcutis Biotherapeutics, Inc. (ARQT) P/E Ratio History
Deep ValueTrading at -202.9x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of September 24, 2026, Arcutis Biotherapeutics, Inc. (ARQT) trades at a price-to-earnings ratio of -202.9x, with a stock price of $26.38 and trailing twelve-month earnings per share of $0.21.
The current P/E is 261% below its 5-year average of 125.8x. Over the past five years, ARQT's P/E has ranged from a low of 125.8x to a high of 125.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, ARQT trades at a 956% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 167.0x.
Relative to the broader market, ARQT trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ARQT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ARQT Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ARQT P/E vs Peers
Commercial Specialty Pharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $1B | 6.1Lowest | 0.59Best | +817%Best | |
| $2B | 14.9 | - | +8% | |
| $180B | 27.8 | 3.36 | -51% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ARQT Historical P/E Data (2026–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $26.22 | $0.21 | 125.8x | +0% |
Average P/E for displayed period: 125.8x
ARQT Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ARQT — Frequently Asked Questions
Quick answers to the most common questions about buying ARQT stock.
What is ARQT's P/E ratio?
Arcutis Biotherapeutics, Inc. (ARQT) trailing twelve-month P/E ratio is -202.9x, based on TTM diluted EPS of $0.21. The 5-year average P/E is 125.8x and the historical range spans 125.8x to 125.8x.
Is ARQT stock overvalued or undervalued?
ARQT trades at -202.9x P/E, below its 5-year average of 125.8x. At the 0th percentile of its historical range (125.8x–125.8x), the stock is priced at a discount to its own history.
Is ARQT stock expensive?
No, ARQT is not expensive on a historical basis. The current P/E of -202.9x is below the 5-year average of 125.8x and sits at the 0th percentile of its valuation range.
What is ARQT's historical P/E range?
Over the past 5 years, ARQT's P/E ratio has ranged from 125.8x to 125.8x, with a median of 125.8x and an average of 125.8x. The current P/E of -202.9x places the stock at the 0th percentile of this range. Full historical data spans 2026–2026.
How does ARQT's P/E compare to the S&P 500?
ARQT trades at -202.9x P/E versus the S&P 500 median of 25.3x. The 902% discount to the market suggests lower growth expectations or perceived higher risk.
How does ARQT's valuation compare to Healthcare peers?
Arcutis Biotherapeutics, Inc. P/E of -202.9x compares to the Healthcare sector median of 23.7x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ARQT's PEG ratio?
ARQT PEG ratio is N/A, based on a P/E of -202.9x and EPS growth of 88.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ARQT's earnings yield?
ARQT earnings yield is N/A, the inverse of its -202.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.